Seven new drugs launched this year are projected to achieve more than $1 billion in sales by 2023, according to a new report published by Clarivate Analytics, which owns BioWorld. Abbvie Inc.'s rheumatoid arthritis candidate, upadacitinib, and Novartis AG's Avexis-sourced gene therapy, Zolgensma (onasemnogene abeparvovec), for spinal muscular atrophy (SMA) could lead the way, raking in $2 billion each, while Fibrogen Inc.'s anemia medicine, roxadustat, isn't far behind with anticipated sales of $1.97 billion in 2023.